 | • レポートコード：MRC2Q12-19016 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、エンドセリン受容体拮抗薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 エンドセリン受容体拮抗薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 エンドセリン受容体拮抗薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 エンドセリン受容体拮抗薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのエンドセリン受容体拮抗薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のエンドセリン受容体拮抗薬の売上および2028年までの予測に焦点を当てています。 エンドセリン受容体拮抗薬のグローバル主要企業には、Gilead Sciences Inc.、Glaxosmithkline Inc.、Sun Pharmaceutical Industries, Inc.、Mylan Pharmaceuticals Inc.、Actavis Pharma, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 エンドセリン受容体拮抗薬市場は、タイプとアプリケーションによって区分されます。世界のエンドセリン受容体拮抗薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 アンブリセンタン、ボセンタン、マシテンタン 【アプリケーション別セグメント】 病院薬局、小売薬局、通販薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - エンドセリン受容体拮抗薬製品概要 - タイプ別市場（アンブリセンタン、ボセンタン、マシテンタン） - アプリケーション別市場（病院薬局、小売薬局、通販薬局） - 調査の目的 ・エグゼクティブサマリー - 世界のエンドセリン受容体拮抗薬販売量予測2017-2028 - 世界のエンドセリン受容体拮抗薬売上予測2017-2028 - エンドセリン受容体拮抗薬の地域別販売量 - エンドセリン受容体拮抗薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別エンドセリン受容体拮抗薬販売量 - 主要メーカー別エンドセリン受容体拮抗薬売上 - 主要メーカー別エンドセリン受容体拮抗薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（アンブリセンタン、ボセンタン、マシテンタン） - エンドセリン受容体拮抗薬のタイプ別販売量 - エンドセリン受容体拮抗薬のタイプ別売上 - エンドセリン受容体拮抗薬のタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売薬局、通販薬局） - エンドセリン受容体拮抗薬のアプリケーション別販売量 - エンドセリン受容体拮抗薬のアプリケーション別売上 - エンドセリン受容体拮抗薬のアプリケーション別価格 ・北米市場 - 北米のエンドセリン受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のエンドセリン受容体拮抗薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのエンドセリン受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のエンドセリン受容体拮抗薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のエンドセリン受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のエンドセリン受容体拮抗薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のエンドセリン受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のエンドセリン受容体拮抗薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのエンドセリン受容体拮抗薬市場規模（タイプ別、アプリケーション別） - 主要国別のエンドセリン受容体拮抗薬市場規模（トルコ、サウジアラビア） ・企業情報 Gilead Sciences Inc.、Glaxosmithkline Inc.、Sun Pharmaceutical Industries, Inc.、Mylan Pharmaceuticals Inc.、Actavis Pharma, Inc. ・産業チェーン及び販売チャネル分析 - エンドセリン受容体拮抗薬の産業チェーン分析 - エンドセリン受容体拮抗薬の原材料 - エンドセリン受容体拮抗薬の生産プロセス - エンドセリン受容体拮抗薬の販売及びマーケティング - エンドセリン受容体拮抗薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - エンドセリン受容体拮抗薬の産業動向 - エンドセリン受容体拮抗薬のマーケットドライバー - エンドセリン受容体拮抗薬の課題 - エンドセリン受容体拮抗薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Endothelin Receptor Antagonist estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Endothelin Receptor Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Endothelin Receptor Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Endothelin Receptor Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Endothelin Receptor Antagonist include Gilead Sciences Inc., Glaxosmithkline Inc., Sun Pharmaceutical Industries, Inc., Mylan Pharmaceuticals Inc. and Actavis Pharma, Inc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Endothelin Receptor Antagonist companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Endothelin Receptor Antagonist market. Further, it explains the major drivers and regional dynamics of the global Endothelin Receptor Antagonist market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Gilead Sciences Inc.
Glaxosmithkline Inc.
Sun Pharmaceutical Industries, Inc.
Mylan Pharmaceuticals Inc.
Actavis Pharma, Inc.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Endothelin Receptor Antagonist Segment by Type
Ambrisentan
Bosentan
Macitentan
Endothelin Receptor Antagonist Segment by Application
Hospital Pharmacy
Retail Pharmacy
Mail Order Pharmacy
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Endothelin Receptor Antagonist market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Endothelin Receptor Antagonist market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Endothelin Receptor Antagonist, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Endothelin Receptor Antagonist, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Endothelin Receptor Antagonist revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Endothelin Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Endothelin Receptor Antagonist revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Gilead Sciences Inc., Glaxosmithkline Inc., Sun Pharmaceutical Industries, Inc., Mylan Pharmaceuticals Inc. and Actavis Pharma, Inc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Endothelin Receptor Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endothelin Receptor Antagonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endothelin Receptor Antagonist revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endothelin Receptor Antagonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Ambrisentan
1.2.3 Bosentan
1.2.4 Macitentan
1.3 Market by Application
1.3.1 Global Endothelin Receptor Antagonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Mail Order Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Endothelin Receptor Antagonist Market Perspective (2017-2028)
2.2 Endothelin Receptor Antagonist Growth Trends by Region
2.2.1 Endothelin Receptor Antagonist Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Endothelin Receptor Antagonist Historic Market Size by Region (2017-2022)
2.2.3 Endothelin Receptor Antagonist Forecasted Market Size by Region (2023-2028)
2.3 Endothelin Receptor Antagonist Market Dynamics
2.3.1 Endothelin Receptor Antagonist Industry Trends
2.3.2 Endothelin Receptor Antagonist Market Drivers
2.3.3 Endothelin Receptor Antagonist Market Challenges
2.3.4 Endothelin Receptor Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endothelin Receptor Antagonist Players by Revenue
3.1.1 Global Top Endothelin Receptor Antagonist Players by Revenue (2017-2022)
3.1.2 Global Endothelin Receptor Antagonist Revenue Market Share by Players (2017-2022)
3.2 Global Endothelin Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Endothelin Receptor Antagonist Revenue
3.4 Global Endothelin Receptor Antagonist Market Concentration Ratio
3.4.1 Global Endothelin Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endothelin Receptor Antagonist Revenue in 2021
3.5 Endothelin Receptor Antagonist Key Players Head office and Area Served
3.6 Key Players Endothelin Receptor Antagonist Product Solution and Service
3.7 Date of Enter into Endothelin Receptor Antagonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Endothelin Receptor Antagonist Breakdown Data by Type
4.1 Global Endothelin Receptor Antagonist Historic Market Size by Type (2017-2022)
4.2 Global Endothelin Receptor Antagonist Forecasted Market Size by Type (2023-2028)
5 Endothelin Receptor Antagonist Breakdown Data by Application
5.1 Global Endothelin Receptor Antagonist Historic Market Size by Application (2017-2022)
5.2 Global Endothelin Receptor Antagonist Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Endothelin Receptor Antagonist Market Size (2017-2028)
6.2 North America Endothelin Receptor Antagonist Market Size by Type
6.2.1 North America Endothelin Receptor Antagonist Market Size by Type (2017-2022)
6.2.2 North America Endothelin Receptor Antagonist Market Size by Type (2023-2028)
6.2.3 North America Endothelin Receptor Antagonist Market Share by Type (2017-2028)
6.3 North America Endothelin Receptor Antagonist Market Size by Application
6.3.1 North America Endothelin Receptor Antagonist Market Size by Application (2017-2022)
6.3.2 North America Endothelin Receptor Antagonist Market Size by Application (2023-2028)
6.3.3 North America Endothelin Receptor Antagonist Market Share by Application (2017-2028)
6.4 North America Endothelin Receptor Antagonist Market Size by Country
6.4.1 North America Endothelin Receptor Antagonist Market Size by Country (2017-2022)
6.4.2 North America Endothelin Receptor Antagonist Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Endothelin Receptor Antagonist Market Size (2017-2028)
7.2 Europe Endothelin Receptor Antagonist Market Size by Type
7.2.1 Europe Endothelin Receptor Antagonist Market Size by Type (2017-2022)
7.2.2 Europe Endothelin Receptor Antagonist Market Size by Type (2023-2028)
7.2.3 Europe Endothelin Receptor Antagonist Market Share by Type (2017-2028)
7.3 Europe Endothelin Receptor Antagonist Market Size by Application
7.3.1 Europe Endothelin Receptor Antagonist Market Size by Application (2017-2022)
7.3.2 Europe Endothelin Receptor Antagonist Market Size by Application (2023-2028)
7.3.3 Europe Endothelin Receptor Antagonist Market Share by Application (2017-2028)
7.4 Europe Endothelin Receptor Antagonist Market Size by Country
7.4.1 Europe Endothelin Receptor Antagonist Market Size by Country (2017-2022)
7.4.2 Europe Endothelin Receptor Antagonist Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endothelin Receptor Antagonist Market Size (2017-2028)
8.2 Asia-Pacific Endothelin Receptor Antagonist Market Size by Type
8.2.1 Asia-Pacific Endothelin Receptor Antagonist Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Endothelin Receptor Antagonist Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Endothelin Receptor Antagonist Market Share by Type (2017-2028)
8.3 Asia-Pacific Endothelin Receptor Antagonist Market Size by Application
8.3.1 Asia-Pacific Endothelin Receptor Antagonist Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Endothelin Receptor Antagonist Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Endothelin Receptor Antagonist Market Share by Application (2017-2028)
8.4 Asia-Pacific Endothelin Receptor Antagonist Market Size by Region
8.4.1 Asia-Pacific Endothelin Receptor Antagonist Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Endothelin Receptor Antagonist Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Endothelin Receptor Antagonist Market Size (2017-2028)
9.2 Latin America Endothelin Receptor Antagonist Market Size by Type
9.2.1 Latin America Endothelin Receptor Antagonist Market Size by Type (2017-2022)
9.2.2 Latin America Endothelin Receptor Antagonist Market Size by Type (2023-2028)
9.2.3 Latin America Endothelin Receptor Antagonist Market Share by Type (2017-2028)
9.3 Latin America Endothelin Receptor Antagonist Market Size by Application
9.3.1 Latin America Endothelin Receptor Antagonist Market Size by Application (2017-2022)
9.3.2 Latin America Endothelin Receptor Antagonist Market Size by Application (2023-2028)
9.3.3 Latin America Endothelin Receptor Antagonist Market Share by Application (2017-2028)
9.4 Latin America Endothelin Receptor Antagonist Market Size by Country
9.4.1 Latin America Endothelin Receptor Antagonist Market Size by Country (2017-2022)
9.4.2 Latin America Endothelin Receptor Antagonist Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endothelin Receptor Antagonist Market Size (2017-2028)
10.2 Middle East & Africa Endothelin Receptor Antagonist Market Size by Type
10.2.1 Middle East & Africa Endothelin Receptor Antagonist Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Endothelin Receptor Antagonist Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Endothelin Receptor Antagonist Market Share by Type (2017-2028)
10.3 Middle East & Africa Endothelin Receptor Antagonist Market Size by Application
10.3.1 Middle East & Africa Endothelin Receptor Antagonist Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Endothelin Receptor Antagonist Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Endothelin Receptor Antagonist Market Share by Application (2017-2028)
10.4 Middle East & Africa Endothelin Receptor Antagonist Market Size by Country
10.4.1 Middle East & Africa Endothelin Receptor Antagonist Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Endothelin Receptor Antagonist Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Gilead Sciences Inc.
11.1.1 Gilead Sciences Inc. Company Details
11.1.2 Gilead Sciences Inc. Business Overview
11.1.3 Gilead Sciences Inc. Endothelin Receptor Antagonist Introduction
11.1.4 Gilead Sciences Inc. Revenue in Endothelin Receptor Antagonist Business (2017-2022)
11.1.5 Gilead Sciences Inc. Recent Developments
11.2 Glaxosmithkline Inc.
11.2.1 Glaxosmithkline Inc. Company Details
11.2.2 Glaxosmithkline Inc. Business Overview
11.2.3 Glaxosmithkline Inc. Endothelin Receptor Antagonist Introduction
11.2.4 Glaxosmithkline Inc. Revenue in Endothelin Receptor Antagonist Business (2017-2022)
11.2.5 Glaxosmithkline Inc. Recent Developments
11.3 Sun Pharmaceutical Industries, Inc.
11.3.1 Sun Pharmaceutical Industries, Inc. Company Details
11.3.2 Sun Pharmaceutical Industries, Inc. Business Overview
11.3.3 Sun Pharmaceutical Industries, Inc. Endothelin Receptor Antagonist Introduction
11.3.4 Sun Pharmaceutical Industries, Inc. Revenue in Endothelin Receptor Antagonist Business (2017-2022)
11.3.5 Sun Pharmaceutical Industries, Inc. Recent Developments
11.4 Mylan Pharmaceuticals Inc.
11.4.1 Mylan Pharmaceuticals Inc. Company Details
11.4.2 Mylan Pharmaceuticals Inc. Business Overview
11.4.3 Mylan Pharmaceuticals Inc. Endothelin Receptor Antagonist Introduction
11.4.4 Mylan Pharmaceuticals Inc. Revenue in Endothelin Receptor Antagonist Business (2017-2022)
11.4.5 Mylan Pharmaceuticals Inc. Recent Developments
11.5 Actavis Pharma, Inc.
11.5.1 Actavis Pharma, Inc. Company Details
11.5.2 Actavis Pharma, Inc. Business Overview
11.5.3 Actavis Pharma, Inc. Endothelin Receptor Antagonist Introduction
11.5.4 Actavis Pharma, Inc. Revenue in Endothelin Receptor Antagonist Business (2017-2022)
11.5.5 Actavis Pharma, Inc. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer